Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies
Biotechnology and Bioengineering · 2024-08 · 121 (8) · 2500-2523
DOI: 10.1002/bit.28737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology and Bioengineering, online erschienen am 28.05.2024. Verfasst von William S Kish und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Process Development, Pfizer Inc., Morrisville, North Carolina, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Capsid. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Recombinant adeno‐associated virus, serotype 9 (rAAV9) has shown promise as a gene therapy vector for muscle and central nervous diseases. High‐dose requirements of these therapies present critical safety considerations and biomanufacturing challenges. Notably, the reduction of empty capsids (ECs), which lack therapeutic transgene, from rAAV9 products is critical to maximize efficacy. Removal of rAAV ECs from full capsids is a major downstream challenge because of their highly similar biophysical characteristics. Ultracentrifugation (UC) reduces ECs but is laborious and difficult to scale. In this paper, to replace a poorly scalable UC process, we developed an anion exchange (AEX) chromatography for rAAV9 EC reduction from full capsids. AEX load preparation by dilution incurred major product loss. The addition of histidine and surfactants to dilution buffers increased yield and reduced aggregation. Elution salts were screened and sodium acetate was found to maximize yield and EC reduction. The most promising load dilution buffer and elution salt were used in combination to form an optimized AEX method. The process reduced ECs three‐fold, demonstrated robustness to a broad range of EC load challenges, and was scaled for large‐scale manufacture. Compared to UC, the AEX method simplified scale‐up, reduced ECs to comparable levels (20%), afforded similar purity and product quality, and increased yield by 14%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gene Therapy Process Development, Pfizer Inc., Morrisville, North Carolina, USA.
- Gene Therapy Process Development, Pfizer Inc., Chesterfield, Missouri, USA.
Förderung
- Pfizer Inc
Zitieren
APA
Kish, W. S., Lightholder, J., Zeković, T., Berrill, A., Roach, M., Wellborn, W. B., & Vorst, E. (2024). Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies. Biotechnology and Bioengineering, 121(8), 2500-2523. https://doi.org/10.1002/bit.28737
Vancouver
Kish WS, Lightholder J, Zeković T, Berrill A, Roach M, Wellborn WB, et al. Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies. Biotechnology and Bioengineering. 2024;121(8):2500-2523. doi:10.1002/bit.28737
BibTeX
@article{Kish2024,
author = {Kish, William S and Lightholder, John and Zeković, Tamara and Berrill, Alex and Roach, Matthew and Wellborn, William B and Vorst, Eric},
title = {Removal of empty capsids from high‐dose adeno‐associated virus 9 gene therapies},
journal = {Biotechnology and Bioengineering},
year = {2024},
volume = {121},
number = {8},
pages = {2500--2523},
doi = {10.1002/bit.28737}
}
EUVIMED